secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001171843-24-003042
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus presents imdusiran data at EASL: 28% achieve HBsAg loss
---------------------------------------------------------------

- Two abstracts on imdusiran (AB-729) accepted for poster and oral presentations at EASL Congress 2024 (June 5-8, Milan).
- 28% of subjects on imdusiran + 24 weeks of IFN achieved HBsAg below lower limit of quantification with anti-HBs.
- Imdusiran followed by VTP-300 maintained lower HBsAg levels; more subjects qualified to stop NA therapy and remain off therapy.
- Additional on-treatment, follow-up, and NA discontinuation data to be presented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324003042/0001171843-24-003042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324003042/f8k_052224.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-003042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer